Catalyst Pharmaceuticals (CPRX) Accumulated Expenses (2010 - 2026)
Catalyst Pharmaceuticals posted quarterly Accumulated Expenses of $125.2 million for Q1 2026, up 29369.88% year-on-year from N/an in Q1 2025, and up 1002.72% on a QoQ basis from $11.4 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) has 17 years of Accumulated Expenses data on file, last reported at $125.2 million in Q1 2026.
- For the quarter ending Q1 2026, Accumulated Expenses rose 29369.88% year-over-year to $125.2 million; the trailing twelve-month figure through Mar 2026 stood at $125.2 million (up 29369.88% YoY), and the FY2025 full-year result was $11.4 million, down 89.09% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $125.2 million, up from $11.4 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $125.2 million in Q1 2026 and bottomed at $425000.0 in Q1 2025.
- The 5-year median for Accumulated Expenses is $48.1 million (2023), against an average of $47.3 million.
- The widest annual swing landed in 2025, when Accumulated Expenses plunged 99.39%; it then jumped 29369.88% in 2026.
- A 5-year view of Accumulated Expenses shows it stood at $53.6 million in 2022, then climbed by 14.28% to $61.3 million in 2023, then jumped by 69.88% to $104.1 million in 2024, then tumbled by 89.09% to $11.4 million in 2025, then surged by 1002.72% to $125.2 million in 2026.
- The last three Accumulated Expenses figures came in at $125.2 million (Q1 2026), $11.4 million (Q4 2025), and $119.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 125.25 Mn |
| Dec 31, 2025 | 11.36 Mn |
| Sep 30, 2025 | 119.64 Mn |
| Jun 30, 2025 | 9.44 Mn |
| Mar 31, 2025 | 425,000.00 |
| Dec 31, 2024 | 104.09 Mn |
| Sep 30, 2024 | 8.01 Mn |
| Jun 30, 2024 | 7.30 Mn |
| Mar 31, 2024 | 69.31 Mn |
| Dec 31, 2023 | 61.27 Mn |
| Sep 30, 2023 | 53.21 Mn |
| Jun 30, 2023 | 48.08 Mn |
| Mar 31, 2023 | 53.32 Mn |
| Dec 31, 2022 | 53.61 Mn |
| Sep 30, 2022 | 42.15 Mn |
| Jun 30, 2022 | 20.17 Mn |
| Mar 31, 2022 | 17.80 Mn |
| Dec 31, 2021 | 24.30 Mn |
| Sep 30, 2021 | 17.86 Mn |
| Jun 30, 2021 | 13.21 Mn |
| Mar 31, 2021 | 11.88 Mn |
| Dec 31, 2020 | 18.50 Mn |
| Sep 30, 2020 | 16.23 Mn |
| Jun 30, 2020 | 14.41 Mn |
| Mar 31, 2020 | 16.29 Mn |
| Dec 31, 2019 | 19.98 Mn |
| Sep 30, 2019 | 13.84 Mn |
| Jun 30, 2019 | 10.82 Mn |
| Mar 31, 2019 | 6.09 Mn |
| Dec 31, 2018 | 7.17 Mn |
| Sep 30, 2018 | 740,939.00 |
| Jun 30, 2018 | 2.16 Mn |
| Mar 31, 2018 | 54,548.00 |
| Dec 31, 2017 | 821,935.00 |
| Sep 30, 2017 | 1.66 Mn |
| Jun 30, 2017 | 1.15 Mn |
| Mar 31, 2017 | 85,534.00 |
| Dec 31, 2016 | 1.16 Mn |
| Sep 30, 2016 | 940,271.00 |
| Jun 30, 2016 | 1.60 Mn |
| Mar 31, 2016 | 1.41 Mn |
| Dec 31, 2015 | 894,846.00 |
| Sep 30, 2015 | 836,340.00 |
| Jun 30, 2015 | 568,886.00 |
| Mar 31, 2015 | 238,842.00 |
| Dec 31, 2014 | 4.04 Mn |
| Sep 30, 2014 | 5.41 Mn |
| Jun 30, 2014 | 1.13 Mn |
| Dec 31, 2013 | 14,539.00 |
| Sep 30, 2013 | 78,697.00 |
| Jun 30, 2013 | 31,256.00 |
| Mar 31, 2013 | 40,290.00 |
| Dec 31, 2012 | 281,002.00 |
| Sep 30, 2012 | 127,912.00 |
| Jun 30, 2012 | 476,063.00 |
| Mar 31, 2012 | 528,962.00 |
| Dec 31, 2011 | 579,385.00 |
| Sep 30, 2011 | 248,616.00 |
| Jun 30, 2011 | 178,125.00 |
| Dec 31, 2010 | 193,028.00 |